Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leucemia, celulă păr - agenți antineoplazici - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, sistemic - imunosupresoare - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - boala pulmonară, obstructivă cronică - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astm - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agenți antineoplazici - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - boala pulmonară, obstructivă cronică - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - daxas este indicat pentru tratamentul de întreţinere al severe cronice obstructive (bpoc) (fev1 post-bronhodilatator mai mică de 50 % prezis) asociate cu bronşită cronică, la pacienţii adulţi cu o istorie de exacerbari frecvente ca supliment la tratamentul bronhodilatator.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - combinatii (naproxen + esomeprazol) - compr. elib. modif. - 500mg/20mg - antiinflamatoare si antireumatice nesteroidiene derivati de acid propionic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astra zeneca ab - combinatii (candesartanum cilexetil+hct) - compr. - 16mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astra zeneca ab - combinatii (candesartanum cilexetil+hct) - compr. - 32mg/25mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic